Vitamin D Deficiency As a Risk Factor for Cystic Fibrosis-related Diabetes in the Scandinavian Cystic Fibrosis Nutritional Study
Overview
Authors
Affiliations
Aims/hypothesis: Many cystic fibrosis patients are vitamin D-insufficient. Cystic fibrosis-related diabetes is a major complication of cystic fibrosis. The literature suggests that vitamin D might possess certain glucose-lowering properties. We aimed to assess the relationship between vitamin D and cystic fibrosis-related glucose intolerance.
Methods: We enrolled 898 cystic fibrosis patients from Sweden, Norway and Denmark. Vitamin D intake was assessed using a seven-day food record. Serum 25-hydroxyvitamin D (s25OHD) and HbA(1c) were measured, and an OGTT was carried out. Multiple linear and logistic regressions were used for HbA(1c) and cystic fibrosis-related diabetes/OGTT result as outcome variables, respectively. Each model was controlled for country, and for known cystic fibrosis-related diabetes risk factors: age, sex, genotype, liver dysfunction, long-term corticosteroid treatment, and lung and pancreatic function.
Results: Degree of vitamin D insufficiency (OR 1.36; p = 0.032) and s25OHD < 30 nmol/l (OR 1.79; p = 0.042) were significant risk factors for cystic fibrosis-related diabetes. Accordingly, HbA(1c) value was positively associated with s25OHD < 30 nmol/l and < 50 nmol/l, as well as with degree of vitamin D insufficiency (adjusted R (2) = 20.5% and p < 0.05 in all). In subgroup analyses, s25OHD < 30 nmol/l determined the HbA(1c) value in paediatric patients (adjusted R (2) = 20.2%; p = 0.017), but not in adults.
Conclusions/interpretation: Vitamin D status is associated with HbA(1c) and diabetes in cystic fibrosis, particularly in children. The study justifies prospective studies on the proposed role of vitamin D deficiency in the pathophysiology of diabetes mellitus.
Development and Evaluation of a Pharmacist-Driven Vitamin D Protocol for a Cystic Fibrosis Clinic.
Yett E, Phan H, Mills A, Fleming J, Majure J, Malinowski S J Pediatr Pharmacol Ther. 2022; 27(4):306-311.
PMID: 35558342 PMC: 9088445. DOI: 10.5863/1551-6776-27.4.306.
Peng Y, Wu M, Alvarez J, Tangpricha V Nutrients. 2021; 13(11).
PMID: 34836301 PMC: 8619506. DOI: 10.3390/nu13114048.
A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis.
Wood C, Hasan S, Darukhanavala A, Tangpricha V J Clin Transl Endocrinol. 2021; 26:100273.
PMID: 34815946 PMC: 8593649. DOI: 10.1016/j.jcte.2021.100273.
Alvarez J, Chong E, Walker D, Chandler J, Michalski E, Grossmann R Metabolism. 2017; 70:31-41.
PMID: 28403943 PMC: 5407388. DOI: 10.1016/j.metabol.2017.02.006.
Qvist T, Taylor-Robinson D, Waldmann E, Olesen H, Hansen C, Mathiesen I J Cyst Fibros. 2015; 15(3):380-5.
PMID: 26482717 PMC: 4893021. DOI: 10.1016/j.jcf.2015.09.007.